06:03:24 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:CRIS from 2023-05-04 to 2024-05-03 - 21 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-30 08:00U:CRISNews ReleaseCuris to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
2024-04-05 07:30U:CRISNews ReleaseCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-04-04 07:30U:CRISNews ReleaseCuris to Present at Upcoming Healthcare Conferences in April
2024-02-08 08:00U:CRISNews ReleaseCuris Provides Fourth Quarter 2023 Business Update
2024-02-01 08:00U:CRISNews ReleaseCuris to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
2024-01-05 08:00U:CRISNews ReleaseCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-12-12 08:00U:CRISNews ReleaseCuris Announces Initial Combination Study Data from its TakeAim Lymphoma Study
2023-12-11 08:00U:CRISNews ReleaseCuris Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
2023-12-06 08:00U:CRISNews ReleaseCuris Announces Three Presentations at ASH
2023-12-05 08:00U:CRISNews ReleaseCuris Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
2023-11-02 08:00U:CRISNews ReleaseCuris Provides Third Quarter 2023 Business Update
2023-10-26 08:30U:CRISNews ReleaseCuris to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
2023-10-06 08:56U:CRISNews ReleaseCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-09-12 08:00U:CRISNews ReleaseCuris Announces Date for the 2nd Symposium on IRAK4 in Cancer
2023-09-06 08:13U:CRISNews ReleaseCuris to Present at Upcoming Healthcare Conferences in September
2023-08-03 16:01U:CRISNews ReleaseCuris Provides Second Quarter 2023 Business Update
2023-07-27 18:25U:CRISNews ReleaseCuris to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
2023-07-06 08:01U:CRISNews ReleaseFDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
2023-07-06 08:00U:CRISNews ReleaseCuris Announces $15.1 Million Registered Direct Offering
2023-05-05 07:30U:CRISNews ReleaseCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-05-04 16:01U:CRISNews ReleaseCuris Provides First Quarter 2023 Business Update